Cargando…

Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells

PURPOSE: Inhibition of vascular endothelial growth factor (VEGF) is a promising strategy to treat retinal complications of diabetes. In contrast to VEGF-A binding ranibizumab, aflibercept also binds to other members of the VEGF family including VEGF-B, but potential effects of this factor on permeab...

Descripción completa

Detalles Bibliográficos
Autores principales: Deissler, Heidrun L., Lang, Gerhard K., Lang, Gabriele E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445774/
https://www.ncbi.nlm.nih.gov/pubmed/25663437
http://dx.doi.org/10.1007/s00417-015-2944-z
_version_ 1782373323789828096
author Deissler, Heidrun L.
Lang, Gerhard K.
Lang, Gabriele E.
author_facet Deissler, Heidrun L.
Lang, Gerhard K.
Lang, Gabriele E.
author_sort Deissler, Heidrun L.
collection PubMed
description PURPOSE: Inhibition of vascular endothelial growth factor (VEGF) is a promising strategy to treat retinal complications of diabetes. In contrast to VEGF-A binding ranibizumab, aflibercept also binds to other members of the VEGF family including VEGF-B, but potential effects of this factor on permeability and angiogenic processes are unclear. Therefore, we studied how VEGF-B variants as single agents or together with VEGF-A(165) might affect proliferation, migration, or barrier function of retinal endothelial cells (REC). Also investigated was the normalization of REC properties with both VEGF-inhibitors to explore if additional targeting of VEGF-B is relevant. METHODS: Stimulation of proliferation or migration of immortalized bovine REC (iBREC) and disturbance of their barrier by exposure to VEGF-B variants (as single factors or together with VEGF-A(165)) was determined with or without VEGF-binding proteins being added. Permeability of iBREC was assessed by measuring their transendothelial resistance (TER) and expression of the tight junction protein claudin-1. RESULTS: VEGF-B(167) and VEGF-B(186) enhanced proliferation of iBREC but these isoforms did not affect cell migration. Interestingly, ranibizumab completely blocked both migration and proliferation induced by VEGF-A plus VEGF-B. Both VEGF-B variants did also not affect barrier function or claudin-1 expression in a normal or high-glucose environment. Accordingly, binding VEGF-A was enough to normalize a reduced TER and reinstate claudin-1 lost during treatment with this factor in combination with VEGF-B. CONCLUSIONS: Important properties and functions of REC seem not to be affected by any VEGF-B variant and targeting the key factor VEGF-A is sufficient to normalize growth factor-disturbed cells of this type. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00417-015-2944-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4445774
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-44457742015-06-01 Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells Deissler, Heidrun L. Lang, Gerhard K. Lang, Gabriele E. Graefes Arch Clin Exp Ophthalmol Basic Science PURPOSE: Inhibition of vascular endothelial growth factor (VEGF) is a promising strategy to treat retinal complications of diabetes. In contrast to VEGF-A binding ranibizumab, aflibercept also binds to other members of the VEGF family including VEGF-B, but potential effects of this factor on permeability and angiogenic processes are unclear. Therefore, we studied how VEGF-B variants as single agents or together with VEGF-A(165) might affect proliferation, migration, or barrier function of retinal endothelial cells (REC). Also investigated was the normalization of REC properties with both VEGF-inhibitors to explore if additional targeting of VEGF-B is relevant. METHODS: Stimulation of proliferation or migration of immortalized bovine REC (iBREC) and disturbance of their barrier by exposure to VEGF-B variants (as single factors or together with VEGF-A(165)) was determined with or without VEGF-binding proteins being added. Permeability of iBREC was assessed by measuring their transendothelial resistance (TER) and expression of the tight junction protein claudin-1. RESULTS: VEGF-B(167) and VEGF-B(186) enhanced proliferation of iBREC but these isoforms did not affect cell migration. Interestingly, ranibizumab completely blocked both migration and proliferation induced by VEGF-A plus VEGF-B. Both VEGF-B variants did also not affect barrier function or claudin-1 expression in a normal or high-glucose environment. Accordingly, binding VEGF-A was enough to normalize a reduced TER and reinstate claudin-1 lost during treatment with this factor in combination with VEGF-B. CONCLUSIONS: Important properties and functions of REC seem not to be affected by any VEGF-B variant and targeting the key factor VEGF-A is sufficient to normalize growth factor-disturbed cells of this type. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00417-015-2944-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-02-08 2015 /pmc/articles/PMC4445774/ /pubmed/25663437 http://dx.doi.org/10.1007/s00417-015-2944-z Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Basic Science
Deissler, Heidrun L.
Lang, Gerhard K.
Lang, Gabriele E.
Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
title Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
title_full Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
title_fullStr Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
title_full_unstemmed Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
title_short Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
title_sort binding of vegf-a is sufficient to abrogate the disturbing effects of vegf-b together with vegf-a on retinal endothelial cells
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445774/
https://www.ncbi.nlm.nih.gov/pubmed/25663437
http://dx.doi.org/10.1007/s00417-015-2944-z
work_keys_str_mv AT deisslerheidrunl bindingofvegfaissufficienttoabrogatethedisturbingeffectsofvegfbtogetherwithvegfaonretinalendothelialcells
AT langgerhardk bindingofvegfaissufficienttoabrogatethedisturbingeffectsofvegfbtogetherwithvegfaonretinalendothelialcells
AT langgabrielee bindingofvegfaissufficienttoabrogatethedisturbingeffectsofvegfbtogetherwithvegfaonretinalendothelialcells